Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis..
Calcif Tissue Int.
(2023).
(2020). Macular edema after uncomplicated cataract surgery: a role for phacoemulsification energy and vitreoretinal interface status?.
Eur J Ophthalmol. 25(3), 192-7.
(2015). Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters..
Int J Clin Pract. 66(6), 602-9.
(2012). Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis..
Horm Metab Res. 41(10), 721-9.
(2009). Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition..
J Clin Endocrinol Metab. 99(9), 3247-55.
(2014). Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide..
Eur J Endocrinol. 158(3), 411-5.
(2008). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015). Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment..
Horm Metab Res. 46(2), 145-9.
(2014). Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature..
Hormones (Athens). 11(4), 419-27.
(2012). Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge..
Curr Opin Endocrinol Diabetes Obes. 18(6), 383-8.
(2011). Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment..
Osteoporos Int. 24(7), 2127-32.
(2013). Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis..
Endocr J. 55(3), 613-6.
(2008). Ιrisin levels in postmenopausal women with an incident hip fracture..
Endocrine. 73(3), 719-722.
(2021). Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study..
J Clin Med. 12(16),
(2023). RANKL inhibition for the management of patients with benign metabolic bone disorders..
Expert Opin Investig Drugs. 18(8), 1085-102.
(2009). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012). Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation..
Calcif Tissue Int.
(2021). Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass..
J Musculoskelet Neuronal Interact. 19(3), 253-257.
(2019). Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases..
J Bone Miner Res. 32(6), 1291-1296.
(2017). Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial..
J Clin Endocrinol Metab. 98(8), 3206-12.
(2013). Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone..
J Bone Miner Metab. 28(1), 108-10.
(2010). Coincidence of severe primary hyperparathyroidism and primary hypothyroidism in a postmenopausal woman with low bone mass--initial conservative management..
J Musculoskelet Neuronal Interact. 11(1), 77-80.
(2011).
(2008).